FDA D.I.S.C.O.: L-Glutamine for Sickle Cell Disease

FDA Drug Information Updates by ReachMD

Aug 17, 201700:05:29Health

FDA medical oncologists discuss the July 7, 2017, approval of l-glutamine to reduce the acute complications of sickle cell disease. Released August 17, 2017

Related Episodes

Continue listening to more episodes from FDA Drug Information Updates.

The FAERS Public Dashboard and its Value to the Pharmaceutical Industry

Jul 31, 2018 - 00:24:45

The FDA has made strides in improving transparency and data access, and has implemented tools to allow th...

FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)

May 4, 2018 - 00:02:59

The Food and Drug Administration (FDA) is warning that the medicine lamotrigine (Lamictal) for seizures a...

FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer

Jan 7, 2018 - 00:08:29

Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the...

FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents

Jan 5, 2018 - 00:02:59

The FDA announced that it is requiring a new class warning and other safety measures for all gadolinium-b...

FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk

Jan 4, 2018 - 00:03:00

The FDA announced that a review of four large clinical safety trials shows that treating asthma with long...

The FDA's Adverse Event Reporting System (FAERS) Public Dashboard

Oct 29, 2017 - 00:09:22

Many listeners may be familiar with the FDA's Adverse Event Reporting System or FAERS. Data in FAERS supp...

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

Jul 28, 2017 - 00:06:00

FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lun...

FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer

Jul 25, 2017 - 00:09:00

FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small...